| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
We aimed with developing human monoclonal antibody against YKL-40 protein, which is specifically expressed on malignant glioma-derived stem cell line established at Shizuoka Cancer Center, using humanized NOG-IL-4 transgenic (TG) mice. After immunization of recombinant human YKL-40 protein to humanized NOG-IL-4 TG mice and verification of antibody titer elevation, 7 anti-YKL-40 antibody-bearing single B cells out of ten million oflymphocytes were identified and sebsequently 4 specific antibody cDNAs were successfully cloned. Finally, 3 human recombinat monoclonal antibodies against YKL-40 protein were obtained using expi293 cells transduced with antibody genes consisting of VH and VL gene. These antibodies have still weak binding affinity for YKL-40 protein, therefore affinity maturation process will be needed using a phage display system.
|
